NCCN Receives $1.5 Million Grant to Research Targeted Therapy in Bladder Cancer

NCCN has been awarded a $1.5 Million grant from Bristol-Myers Squibb Company and ImClone Systems Incorporated to fund research on the antibody cetuximab in patients with bladder cancer. The novel targeted therapy has proven effective in various other types of cancer including colorectal and head and neck. The University of Michigan Comprehensive Cancer Center is the coordinating center for the study. November 24, 2008 FORT WASHINGTON, PA — The National Comprehensive Cancer Network (NCCN...
Source: National Comprehensive Cancer Network Oncology Research Program - Category: Cancer & Oncology Source Type: news